Beijing, July 29, 2024, The Europe Today: On Monday, China unveiled two comprehensive guidelines aimed at the prevention and treatment of diabetes and chronic respiratory diseases, to be implemented from 2024 to 2030. The initiative, driven by multiple departments including the National Health Commission (NHC), seeks to significantly enhance public health outcomes by the end of the decade.
The diabetes prevention and treatment framework aims to ensure that by 2030, over 60 percent of residents aged 18 and above will have awareness of the disease. Additionally, the coverage rate of standardized management services for type 2 diabetes patients at the primary care level is expected to exceed 70 percent.
Parallelly, the guidelines for chronic respiratory diseases aim to refine the existing prevention and control system, targeting a reduction in the mortality rate of chronic respiratory diseases among individuals aged 70 and under to 8.1 per 100,000 or below by 2030.
The NHC highlighted that chronic diseases have become a major barrier to improving healthy life expectancy in China, with data revealing that over 80 percent of deaths in the country are attributed to major chronic diseases, including cardiovascular and cerebrovascular diseases, cancer, diabetes, and chronic respiratory diseases.
Current statistics indicate that China has over 30 million diabetic patients aged 65 and above, and around 100 million individuals suffering from chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma.
In recent years, China has established the world’s largest disease and health risk surveillance network, which has contributed to a decline in the premature mortality rate of major chronic diseases from 18.5 percent in 2015 to 15.3 percent in 2021.
These new guidelines represent a concerted effort by the Chinese government to combat the rising tide of chronic diseases and improve the overall health and well-being of its population.
